Our commitment to patients

Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by inflammation in the colon and the rectum. Some symptoms may include bloody diarrhea, abdominal pain, bowel urgency, and frequent bowel movements. Approximately 1.3 million individuals in the U.S. have UC, with tens of thousands of new patients diagnosed annually. Despite recent advancements in treatment, a significant number of people living with UC continue to suffer from active disease. Today’s treatments are associated with many challenges, including low rates of remission and a high frequency of injections that may lead to poor compliance.

Crohn’s disease (CD) is a chronic inflammatory disorder characterized by inflammation in any part of the gastrointestinal tract, from the mouth to the rectum. Some symptoms may include abdominal pain, diarrhea, weight loss, fatigue, and complications such as strictures or fistulas. Approximately 1 million individuals in the U.S. have CD, with tens of thousands of new patients diagnosed annually. Despite recent advancements in treatment, a significant number of people living with CD continue to suffer from active disease. Today’s treatments are associated with many challenges, including low rates of remission and a high frequency of injections that may lead to poor compliance.

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune condition that primarily affects the joints. It is characterized by pain, stiffness and swelling of one or more joints and can progress from mild swelling of the joints in early stages to severe deformations of the feet, ankles, and hands in late/severe stages. RA is thought to arise from an aberrant immune response to modified proteins in mucosal tissue and the synovium, driven by genetic risk factors and environmental stressors. RA affects more than 1.5 million individuals in the U.S., with stable-to-increasing incidence of ~40 per 100,000 individuals. Despite several advanced treatment options, a significant number of people living with RA continue to suffer from active disease. Today’s treatments are associated with many challenges, including low rates of remission, loss of response, and a high frequency of injections that may lead to poor compliance.

Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune condition that typically affects both the joints and skin. It is characterized by pain, stiffness, and swelling of one or more joints and can progress from mild swelling of the joints in early stages to severe deformations of the joints in late/severe stages. Other characteristics can include psoriasis (PsO; scaly patches on the skin and/or nail discoloration and pitting), dactylitis (swollen fingers and toes), and spondylitis (painful inflammation in the spine). PsA is thought to arise from genetic and environmental triggers, though the pathogenesis is multifactorial and not well understood. PsA affects approximately 0.8 million individuals in the U.S., with estimates suggesting that up to 15% of PsO patients may have undiagnosed PsA. Despite several advanced treatment options, a significant number of people living with PsA continue to suffer from active disease. Today’s treatments are associated with many challenges, including inability to adequately address both joint and skin symptoms, loss of response, and a high frequency of injections that may lead to poor compliance.

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that primarily affects the axial skeleton (spine), with radiographic and non-radiographic subtypes. It is characterized by persistent back pain, stiffness, fatigue, joint stiffness, and frequent occurrence of extra-articular manifestations, such as anterior uveitis, IBD, and psoriasis. axSpA is thought to arise when biomechanical stress, genetics, environmental triggers, and other factors lead to overactivation of the immune system in the spine. axSpA affects an estimated 3 million individuals in the U.S., though only approximately 0.9 million of those are diagnosed. Despite some advanced treatment options, a significant number of people living with axSpA continue to suffer from active disease. Today’s treatments are associated with many challenges, including incomplete / loss of response, lack of MOAs to cycle through, and a high frequency of injections that may lead to poor compliance.